TrialBlood advances2021

Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies.

Matthew S Davids et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.